Maddi Hebebrand, MC, Associate Editor

In his presentation at Winter Clinical Miami, Del Rosso covered new and emerging therapies as well as successful off-label uses.

Researchers found the combination therapy significantly reduced rosacea severity, with 64% achieving mild or normal status in just 4 weeks.

Jason Hawkes, MD, MS, discusses unmet needs in chronic urticaria care and challenges outdated testing practices.

Fast-acting therapies like remibrutinib bring new hope to patients with chronic urticaria who don’t respond to antihistamines.

A recent study found chronic inflammation in psoriasis may contribute to cognitive decline.

Noor emphasizes that patient access is the primary consideration when deciding to use the buy-and-bill model.

Hawkes combines personal experience and clinical expertise to treat urticaria patients.

Explore the top headlines of the week including the growth of NPs and PAs in the field, clinical trial updates, and advancements in therapy.

Mitragotri's work bridges advanced drug development and skin care for tailored treatments.

The new dosing option offers convenience for those managing plaque psoriasis, PsA, and hidradenitis suppurativa.

Researchers found patients with conditions like asthma or dermatitis are more likely to develop early, severe, and prolonged forms of alopecia areata.

Researchers found emotional resilience can mitigate acne's psychological and social challenges.

Effective PsA management requires balancing clinical goals with patient-reported challenges like fatigue and daily disruptions.

The analysis findings support the potential use of zinc and vitamin D supplementation in managing alopecia areata.

Cemiplimab demonstrated a 68% reduction in recurrence risk for high-risk CSCC in the phase 3 C-POST trial, according to Regeneron’s latest findings.

A 25-day BioLab study revealed their protein-rich wound gel outpaces alternatives, setting the stage for clinical trials.

Data augmentation techniques like cropping and blurring allow AI models to overcome limited datasets, improving skin cancer detection rates.

Explore the top headlines of the week including clinical trial updates, FDA announcements, and expert insights.

Advancements in therapeutic agents demand innovative strategies for safe, localized skin treatments, Mitragotri argues.

A study revealed ruxolitinib cream's rapid, lasting benefits in pediatric eczema without systemic safety concerns over a 52-week trial period.

Mitragotri said new innovations like ionic liquid-based delivery systems can offer better treatment for immunodermatological conditions.

Designed to mimic natural tissue scaffolds, DermiSphere hDRT offers innovative support for cellular infiltration and healing in reconstructive surgery.

The innovative technology is unlocking new possibilities in dermatology by improving the solubility and permeability of drugs for topical use.

Experts explore innovative therapies, psychosocial impacts, and education strategies for managing atopic dermatitis in a Dermatology Times video series.

While zinc deficiency shows strong ties to SD, researchers stated vitamin D's role is less clear and may depend on genetic factors.

By addressing skin health proactively, runners can enhance performance and longevity in the sport while minimizing discomfort and long-term dermatological damage.

Repibresib’s localized delivery minimizes systemic exposure while targeting inflammatory pathways, a novel approach for vitiligo management.

Explore the top headlines of the week including 2025 PDUFA dates, 2024 interview insights, and awareness dates to add to your calendar.

Unlike bakuchiol, which exhibited toxicity at higher concentrations, SME demonstrated no cytotoxic effects in vitro.

Researchers found significant clinical benefits and tolerability with dual therapy for patients unresponsive to dupilumab alone.